3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Lymphangioma
2
Hyperglycemia
2
Hereditary Sensory and Autonomic Neuropathies
2
Vascular Malformations
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases, Vascular
1
Melanoma
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Arteriovenous Malformations
1
Advanced HER2+Breast Cancer
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
25
Cisplatin
23
Carboplatin
18
Magnetic Resonance Spectroscopy
16
Paclitaxel
15
Specimen Handling
14
Pemetrexed
11
durvalumab
9
Radiotherapy, Intensity-Modulated
8
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Nivolumab
7
Radiation
6
Docetaxel
6
Cetuximab
6
Biopsy
6
osimertinib
5
cemiplimab
5
Taxes
5
Radiotherapy
5
Ipilimumab
5
Cyclophosphamide
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
poly ICLC
4
cabozantinib
4
atezolizumab
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
Alpelisib
×
1 year
×
Clear all
No trials found.